Immune checkpoint blockade opens a new way to cancer immunotherapy
- 3 December 2018
- journal article
- review article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (6) , 8541-8549
Abstract
Among the main promising systems to triggering therapeutic antitumor immunity is the blockade of immune checkpoints. Immune checkpoint pathways regulate the control and eradication of infections, malignancies, and resistance against a host of autoantigens. Initiation point of the immune response is T cells, which have a critical role in this pathway. As several immune checkpoints are initiated by ligand–receptor interactions, they can be freely blocked by antibodies or modulated by recombinant forms of ligands or receptors. Antibodies against cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA‐4) were the first immunotherapeutics that achieved the US Food and Drug Administration approval. Preliminary clinical results with the blockers of additional immune checkpoint proteins, such as programmed cell death protein 1 (PD‐1) indicate extensive and different chances to boost antitumor immunity with the objective of conferring permanent clinical effects. This study provides an overview of the immune checkpoint pathways, including CTLA‐4, PD‐1, lymphocyte activation gene 3, T‐cell immunoglobulin and mucin domain 3, B7‐H3, and diacylglycerol kinase α and implications of their inhibition in the cancer therapy.Keywords
This publication has 107 references indexed in Scilit:
- Tumor immunity times out: TIM-3 and HMGB1Nature Immunology, 2012
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1Nature Immunology, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2Journal of Experimental Medicine, 2012
- Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4Science, 2011
- Camouflage and sabotage: tumor escape from the immune systemCancer Immunology, Immunotherapy, 2011
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responsesJournal of Experimental Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomasLaboratory Investigation, 2010
- Soluble CD276 (B7‐H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serumImmunology, 2008